Thais Pereira-Veiga
Overview
Explore the profile of Thais Pereira-Veiga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
313
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gotze J, Meissner K, Pereira-Veiga T, Belloum Y, Schneegans S, Kropidlowski J, et al.
J Exp Clin Cancer Res
. 2025 Jan;
44(1):14.
PMID: 39815324
Background: The lack of predictive biomarkers contributes notably to the poor outcomes of patients with pancreatic ductal adenocarcinoma (PDAC). Cancer-associated fibroblasts (CAFs) are the key components of the prominent PDAC...
2.
Gorgulho J, Loosen S, Masood R, Giehren F, Pagani F, Buescher G, et al.
J Exp Clin Cancer Res
. 2024 Nov;
43(1):298.
PMID: 39511626
Background: The major breakthrough in cancer therapy with immune checkpoint inhibitors (ICIs) has highlighted the important role of immune checkpoints in antitumoral immunity. However, most patients do not achieve durable...
3.
Pereira-Veiga T, Bravo S, Gomez-Tato A, Yanez-Gomez C, Abuin C, Varela V, et al.
Mol Cell Proteomics
. 2024 May;
23(5):100774.
PMID: 38735273
No abstract available.
4.
Pereira-Veiga T, Behrens B, Broekmaat J, Oomens L, Stevens M, Tibbe A, et al.
Methods Mol Biol
. 2024 Jan;
2752:65-70.
PMID: 38194028
Tumor heterogeneity has a major role in the development of tumor evasion and resistance to treatments. To study and understand the intrinsic heterogeneity of cancer cells, the use of single-cell...
5.
Reimer F, Bryan S, Legler K, Karn T, Eppenberger-Castori S, Matschke J, et al.
Cancer Cell Int
. 2023 Mar;
23(1):47.
PMID: 36927383
Background: The disruption of epithelial features represents a critical step during breast cancer spread. In this context, the dysregulation of desmosomal proteins has been associated with malignant progression and metastasis...
6.
Abdo M, Belloum Y, Heigener D, Welker L, von Weihe S, Schmidt M, et al.
Mol Oncol
. 2023 Mar;
17(5):737-746.
PMID: 36892210
Alternative sources of tumour information need to be explored in patients with non-small cell lung cancer (NSCLC). Here, we compared programmed cell death ligand 1 (PD-L1) expression on cytology imprints...
7.
Pereira-Veiga T, Bravo S, Gomez-Tato A, Yanez-Gomez C, Abuin C, Varela V, et al.
Mol Cell Proteomics
. 2022 Dec;
21(12):100435.
PMID: 36519745
Metastasis is the primary cause of death for most breast cancer (BC) patients who succumb to the disease. During the hematogenous dissemination, circulating tumor cells interact with different blood components....
8.
Nitschke C, Markmann B, Konczalla L, Kropidlowski J, Pereira-Veiga T, Scognamiglio P, et al.
Biomedicines
. 2022 Nov;
10(11).
PMID: 36428523
Background: Circulating Cancer Associated Macrophage-like cells (CAMLs) have been described as novel liquid biopsy analytes and unfavorable prognostic markers in some tumor entities, with scarce data for Pancreatic Ductal Adenocarcinomas...
9.
Pereira-Veiga T, Schneegans S, Pantel K, Wikman H
Cell Rep
. 2022 Aug;
40(9):111298.
PMID: 36044866
Circulating tumor cells (CTCs) are the seeds of distant metastasis, and the number of CTCs detected in the blood of cancer patients is associated with a worse prognosis. CTCs face...
10.
Pereira-Veiga T, Gonzalez-Conde M, Leon-Mateos L, Pineiro-Cid R, Abuin C, Muinelo-Romay L, et al.
Clin Exp Metastasis
. 2021 Feb;
38(2):239-251.
PMID: 33635497
CTCs have extensively been used for the monitoring and characterization of metastatic prostate cancer, but their application in the clinic is still very scarce. Besides, the resistance mechanisms linked to...